IN2012DN00971A - - Google Patents

Info

Publication number
IN2012DN00971A
IN2012DN00971A IN971DEN2012A IN2012DN00971A IN 2012DN00971 A IN2012DN00971 A IN 2012DN00971A IN 971DEN2012 A IN971DEN2012 A IN 971DEN2012A IN 2012DN00971 A IN2012DN00971 A IN 2012DN00971A
Authority
IN
India
Prior art keywords
adrenoceptor
activation
prevention
formula
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Scott D Edmondson
Lehua Chang
Gregori J Morriello
Christopher J Moyes
Nam Fung Kar
Dong-Ming Shen
Cheng Zhu
Neville J Anthony
Philip Jones
Graham F Smith
Mark E Scott
Christopher F Thompson
Joon Jung
Carolyn Cammarano
Dawn Marie Hoffman
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2012DN00971A publication Critical patent/IN2012DN00971A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
IN971DEN2012 2009-08-27 2010-08-24 IN2012DN00971A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23748709P 2009-08-27 2009-08-27
PCT/US2010/046468 WO2011025774A1 (en) 2009-08-27 2010-08-24 Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
IN2012DN00971A true IN2012DN00971A (ru) 2015-04-10

Family

ID=43628346

Family Applications (1)

Application Number Title Priority Date Filing Date
IN971DEN2012 IN2012DN00971A (ru) 2009-08-27 2010-08-24

Country Status (10)

Country Link
US (1) US8604038B2 (ru)
EP (1) EP2470012B1 (ru)
JP (1) JP5671538B2 (ru)
CN (1) CN102573471B (ru)
AU (1) AU2010286694B2 (ru)
BR (1) BR112012004333A2 (ru)
CA (1) CA2770475C (ru)
IN (1) IN2012DN00971A (ru)
MX (1) MX2012002366A (ru)
WO (1) WO2011025774A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140134B (zh) * 2010-07-23 2015-07-29 默沙东公司 新吡咯烷衍生的β3肾上腺素能受体激动剂
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EA030145B1 (ru) 2010-08-03 2018-06-29 Велисепт Терапьютикс, Инк. Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015050798A1 (en) * 2013-10-03 2015-04-09 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US20180186755A1 (en) * 2015-07-01 2018-07-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10408983B2 (en) 2016-08-16 2019-09-10 Moxtek, Inc. Durable, high performance wire grid polarizer having permeable junction between top protection layer
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2020123847A1 (en) * 2018-12-12 2020-06-18 Rutgers, The State University Of New Jersey Organic compounds
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8702355A1 (es) * 1981-07-22 1985-07-01 Syntex Inc Procedimiento para la preparacion de antidepresivos reguladores del sistema cardiovascular a base de pirrolidina sustituida
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP2274296B1 (en) * 2008-04-04 2012-10-17 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US8354403B2 (en) * 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
AU2010286694A1 (en) 2012-03-08
EP2470012A1 (en) 2012-07-04
EP2470012B1 (en) 2014-11-05
CN102573471B (zh) 2014-11-26
CA2770475A1 (en) 2011-03-03
MX2012002366A (es) 2012-03-29
JP5671538B2 (ja) 2015-02-18
AU2010286694B2 (en) 2013-09-12
WO2011025774A1 (en) 2011-03-03
US8604038B2 (en) 2013-12-10
CA2770475C (en) 2017-06-27
JP2013503167A (ja) 2013-01-31
BR112012004333A2 (pt) 2015-09-08
EP2470012A4 (en) 2013-01-09
US20120225886A1 (en) 2012-09-06
CN102573471A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
IN2012DN00971A (ru)
IN2014CN04907A (ru)
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
IN2012DN03883A (ru)
PH12014500053A1 (en) Proteasome inhibitors
MY151246A (en) Benzofuranyl derivatives
MX2012000565A (es) Derivados de triterpeno tipo lupeol como antivirales.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
GB201118656D0 (en) New compounds
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
UA107783C2 (en) Isoindoline compounds for use in treating cancer
IN2012MN02591A (ru)
MX2012006730A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2012004780A (es) Inhibidores de akt.
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
IN2012DN02471A (ru)
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof